MaxCyte Inc (MXCT)
Industry Medical Devices
Sell
240.00p
Buy
244.00p
5.00p (+1.99%)
Prices updated at 21 Mar 2025, 16:35 GMT
| Prices minimum 15 mins delay
Prices in GBX
MaxCyte Inc is a provider of technological solutions to pharmaceutical companies. Its key product is electroporation technology which is sold to companies which are engaged in drug discovery and development.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 41m | 39m | |
| 37m | 32m | |
| -48m | -51m | |
| -116.98 | -132.54 | |
| -38m | -41m | |
| -44m | -46m | |
| Sales, General and administrative | 57m | 56m |
| Interest expenses | - | - |
| Provision for income taxes | - | - |
| Operating expenses | 85m | 83m |
| Income before taxes | -38m | -41m |
| Net income available to common shareholders | -38m | -41m |
| -0.37 | -0.39 | |
| Net interest income | 10m | 10m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.37 | -0.39 |
| Free cash flow per share | -0.2575 | -0.1621 |
| Book value/share | 1.7631 | 1.6081 |
| Debt equity ratio | 0.077397 | 0.083248 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 190m | 172m |
| Current liabilities | 18m | 16m |
| Total capital | 232m | 206m |
| Total debt | 19m | 18m |
| Total equity | 232m | 206m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 268m | 239m |
| Total liabilities | - | - |
| Cash and cash equivalents | 47m | 28m |
| Common stock | 104m | 106m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 11m | 47m |
| Cash dividends paid | - | - |
| -25m | -29m | |
| Investments (gains) losses | 55m | 7m |
| 47m | 28m | |
| Net income | - | - |
| -22m | -28m | |
| -4m | -2m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
